MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma

References

• Ng AK. Diffuse large B-cell lymphoma. SeminRadiat Oncol 2007;17:169–75.
   Web of Science ®Google Scholar
• Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 2007;67:1689–1702.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007;12:664–89.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Diffuse large cell lymphoma. CurrOpin Oncol 2001;13:325–34.
   Web of Science ®Google Scholar
• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-celllymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Han MH, Eom HS, Park WS, Yun T, Park S, Kim HJ, et al.. Detection of circulating lymphoma cellsin patients with non-Hodgkin lymphoma using MAGE-A3 geneexpression in peripheral blood. Leuk Res 2010;34:1127–31.
   PubMed Web of Science ®Google Scholar
• Miranda EI. MAGE, biological functions and potential clinicalapplications. Leuk Res 2010;34:1121–2.
   PubMed Web of Science ®Google Scholar
• Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, et al.. Detection of MAGE-A transcripts inbone marrow is an independent prognostic factor in operable non-small-celllung cancer. Clin Cancer Res 2007;13:3840–7.
   PubMed Web of Science ®Google Scholar
• Condomines M, Hose D, Raynaud P, Hundemer M, de Vos J, Baudard M, et al.. Cancer/testis genes in multiple myeloma:expression patterns and prognosis value determined by microarray analysis. JImmunol 2007;178:3307–15.
   PubMed Web of Science ®Google Scholar
• Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, et al.. MAGE-A and NY-ESO-1 expression in cervicalcancer: prognostic factors and effects of chemotherapy. AmJ Obstet Gynecol 2008;198:99.e1–7.
   Web of Science ®Google Scholar
• Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, et al.. Prognostic relevance of MAGE-A4 tumorantigen expression in transitional cell carcinoma of the urinary bladder:a tissue microarray study. Int J Cancer 2002;100:702–5.
   PubMed Web of Science ®Google Scholar
• Martinez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J, et al.. mRNA expression of MAGE-A3gene in leukemia cells. Leuk Res 2007;31:33–7.
   PubMed Web of Science ®Google Scholar
• Miranda EI, Garrido-Guerrero E, García-Carrancá A, Gariglio P. Immunoprecipitation of SV40 replicating minichromosomescomplexed with bacteriophage T4 gene 32 protein. NuclAcids Res 1992;20:903–7.
   PubMed Web of Science ®Google Scholar
• Salazar AM, Ostrosky-Wegman P, Menéndez D, Miranda EI, García-Carrancá A, Rojas E. Induction of P53 protein expression by sodiumarsenite. Mutat Res 1997;381:259–65.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958;53:457–81.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rankorder statistics arising in its consideration. CancerChemother Rep 1966;50:163–70.
   PubMedGoogle Scholar
• Czuczman MS, Grillo-López AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P. Prognostic factors for non-Hodgkin’slymphoma patients treated with chemotherapy may not predict outcome in patientstreated with rituximab. Leuk Lymphoma 2006;47:1830–40.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc HematolEduc Program 2004;:221–36.
   Google Scholar
• TheInternational Non-Hodgkin’s Lymphoma Prognostic Factors Project. Apredictive model for aggressive non-Hodgkin’s lymphoma. NEngl J Med 1993;329:987–94.
   PubMed Web of Science ®Google Scholar
• Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F, et al.. Expression of MAGE genes in primaryand metastatic cutaneous melanoma. Int J Cancer 1995;63:375–80.
   PubMed Web of Science ®Google Scholar
• Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, et al.. NY-ESO-1 expression and immunogenicityassociated with transitional cell carcinoma: correlation with tumor grade. CancerRes 2001;61:4671–4.
   Web of Science ®Google Scholar
• Dhodapkar MV, Osman K, Teruya-Feldastein J, Filippa D, Hedvat CV, Iversen K, et al.. Expression of cancer/testis (CT) antigensMAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies isheterogeneous and correlates with site, stage and risk status of disease. CancerImmun 2003;3:9–16.
   PubMedGoogle Scholar
• Liggins AP, Lim SH, Soilleux EJ, Pulford K, Banham AH. A panel of cancer–testis genes exhibitingbroad-spectrum expression in haematological malignancies. CancerImmun 2010;10:8–19.
   PubMedGoogle Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al.. Prediction of survival in diffuse largeB-cell lymphoma based on the expression of six genes. NEngl J Med 2004;350:1828–37.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al.. Confirmation of the molecular classificationof diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–82.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al.. The use of molecular profiling to predictsurvival after chemotherapy for diffuse large B-cell lymphoma. NEngl J Med 2002;346:1937–47.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al.. Diffuse large B-cell lymphoma outcomeprediction by gene-expression profiling and supervised machine learning. NatMed 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Kawano R, Karube K, Kikuchi M, Takeshita M, Tamura K, Uike N, et al.. Oncogene associated cDNA microarrayanalyses shows PRAME gene expression is a marker for response to anthracyclinecontaining chemotherapy in patients with diffuse large B-cell lymphoma. JClin Exp Hematopathol 2009;49:1–7.
   PubMedGoogle Scholar
• Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3ζ mediates resistance of diffuselarge B-cell lymphoma to an anthracycline-based chemotherapeutic regimen. JBiol Chem 2009;284:22379–89.
   PubMed Web of Science ®Google Scholar
• Xie X, Wacker H, Huang S, Regitz E, Preuss K-D, Romeike B, et al.. Differential expression of cancer testisgenes in histological subtypes of non-Hodgkin’s lymphomas. ClinCancer Res 2003;9:167–73.
   Web of Science ®Google Scholar
• Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, et al.. Cytolytic T-cell response to the PASD1cancer testis antigen in patients with diffuse large B-cell lymphoma. BrJ Haematol 2009;146:396–407.
   PubMed Web of Science ®Google Scholar